BETTA PHARMACEUTICALS: The company has corresponding preclinical project establishment for the KRAS target
On July 19th, BETTA PHARMACEUTICALS stated on the interactive platform that the company has corresponding preclinical project establishment for the KRAS target, and the team is currently accelerating progress to submit the clinical trial application as soon as possible
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments